UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 350

Sortiert nach

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Annals of oncology, 2022-05, Vol.33 (5), p.534-543

2022

Volltextzugriff (PDF)

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Annals of oncology, 2018-12, Vol.29 (12), p.2328-2333

2018

Volltextzugriff (PDF)

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Annals of oncology, 2023-12, Vol.34 (12), p.1152-1164

2023

Volltextzugriff (PDF)

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

Annals of oncology, 2023-02, Vol.34 (2), p.152-162

2023

Volltextzugriff (PDF)

P120 Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial

Breast (Edinburgh), 2023-04, Vol.68, p.S60-S60

2023

Volltextzugriff (PDF)

Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial

Annals of oncology, 2019-05, Vol.30, p.iii73-iii73

2019

Volltextzugriff (PDF)

CompLEEment-1: phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi39-vi40

2017

Volltextzugriff (PDF)

Ribociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii105-viii106

2018

Volltextzugriff (PDF)

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii108-viii108

2018

Volltextzugriff (PDF)

Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii710-viii710

2018

Volltextzugriff (PDF)

Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer

Annals of oncology, 2013-01, Vol.24 (1), p.264-265

2013

Volltextzugriff (PDF)

Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy)

Annals of oncology, 2017-10, Vol.28, p.vi81-vi81

2017

Volltextzugriff (PDF)

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

Annals of oncology, 2017-10, Vol.28, p.vi1-vi1

2017

Volltextzugriff (PDF)

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

European journal of cancer (1990), 2018-01, Vol.88, p.10-20

2018

Volltextzugriff (PDF)

Hyperthermic Intraperitoneal Chemotherapy in Ephitelial Ovarian Cancer should be proposed in eight time points

European journal of surgical oncology, 2014-08, Vol.40 (8), p.1028-1029

2014

Volltextzugriff (PDF)

Hypofractionated radiotherapy after conservative surgery in breast cancer patients: a phase I-II trial (MARA-1)

European journal of cancer (1990), 2017-02, Vol.72, p.S28-S29

2017

Volltextzugriff (PDF)

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

ESMO open, 2021-02, Vol.6 (1), p.100019, Article 100019

2021

Volltextzugriff (PDF)

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry

Bone marrow transplantation (Basingstoke), 2013-03, Vol.48 (3), p.414-418

2013

Volltextzugriff (PDF)

EP-1154: Post mastectomy radiotherapy and periprosthesic capsule contraction: a clinico-pathological analysis

Radiotherapy and oncology, 2016-04, Vol.119, p.S551-S551

2016

Volltextzugriff (PDF)

EP-1152: Impact on late toxicity of IMRT with concomitant boost after breast conserving surgery

Radiotherapy and oncology, 2016-04, Vol.119, p.S550-S550

2016

Volltextzugriff (PDF)

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

European journal of cancer (1990), 2015-09, Vol.51, p.S532-S532

2015

Volltextzugriff (PDF)

Brio: A European Prospective Observational Study to Assess the Burden of Disease and Treatment in Metastatic Breast Cancer (Mbc) Patients Treated with Oral Vinorelbine (Nvboral) or Intravenous Vinorelbine (Ivvino)

Value in health, 2014-11, Vol.17 (7), p.A647-A647

2014

Volltextzugriff (PDF)

Reply to “18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in predicting pathologic complete response after neoadjuvant chemotherapy: The early metabolic response is the answer”

European journal of cancer (1990), 2013-11, Vol.49 (16), p.3575-3576

2013

Volltextzugriff (PDF)

Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy

European journal of cancer (1990), 2013-05, Vol.49 (7), p.1539-1545

2013

Volltextzugriff (PDF)

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2017-10, Vol.390 (10106), p.1949-1961

2017

Volltextzugriff (PDF)

1 – 25 von 350

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(324)
Mit Volltextzugriff
(309)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(121)
Life Sciences & Biomedicine
(119)
Humans
(114)
Female
(84)
Middle Aged
(75)
Oncology
(70)
Aged
(62)
Adult
(57)
Male
(49)
Hematology
(44)
Biological And Medical Sciences
(37)
Medical Sciences
(36)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(33)
Chemotherapy
(32)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(27)
Multiple Myeloma
(27)
Treatment Outcome
(26)
Multiple Myeloma - Drug Therapy
(22)
Prognosis
(21)
Tumors
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(52)
European Journal Of Cancer
(25)
Radiotherapy And Oncology
(20)
Journal Of Clinical Oncology
(17)
Cancer Research
(14)
Blood
(12)
Revue De Théologie Et De Philosophie
(11)
Hemasphere
(10)
Haematologica
(9)
The Lancet Oncology
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis

P120 Cardiac safety of pertuzumab, trastuzumab and standard chemotherapy as neoadjuvant treatment for HER2 positive breast cancer: real world data from NeoPowER trial

Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial

CompLEEment-1: phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC

Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer

Three-monthly dynamic evaluation of CEA and CA15-3 and 18-FDG PET vs usual practice in the follow-up of early breast cancer patients: a prospective, multicenter, randomized trial (KRONOS – Patient-Oriented New Surveillance-Study Italy)

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study

Hyperthermic Intraperitoneal Chemotherapy in Ephitelial Ovarian Cancer should be proposed in eight time points

Hypofractionated radiotherapy after conservative surgery in breast cancer patients: a phase I-II trial (MARA-1)

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry

EP-1154: Post mastectomy radiotherapy and periprosthesic capsule contraction: a clinico-pathological analysis

EP-1152: Impact on late toxicity of IMRT with concomitant boost after breast conserving surgery

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

Brio: A European Prospective Observational Study to Assess the Burden of Disease and Treatment in Metastatic Breast Cancer (Mbc) Patients Treated with Oral Vinorelbine (Nvboral) or Intravenous Vinorelbine (Ivvino)

Reply to “18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in predicting pathologic complete response after neoadjuvant chemotherapy: The early metabolic response is the answer”

Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Suchergebnisse filtern